{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:39Z","timestamp":1789545639667,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1189490"],"award-info":[{"award-number":["#1189490"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1151512"],"award-info":[{"award-number":["GNT1151512"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1177784"],"award-info":[{"award-number":["GNT1177784"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2008447"],"award-info":[{"award-number":["GNT2008447"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1194811"],"award-info":[{"award-number":["GNT1194811"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015675","name":"National Blood Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015675","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Melbourne McKenzie Fellowship, Australia","award":["2025MCK182"],"award-info":[{"award-number":["2025MCK182"]}]},{"name":"Medical Research Future Fund, Australia","award":["MRF2017480"],"award-info":[{"award-number":["MRF2017480"]}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prophylactic immunoglobulin (Ig) is used to prevent infections in patients with hypogammaglobulinaemia due to haematological malignancies (HM). Ig can be administered intravenously (IVIg) in hospital or self-administered subcutaneously (SCIg) at home, using different dosing regimens but with comparable effectiveness. In Australia, Ig product costs alone were AU$915.7 million in 2022\/2023, 60% of the national blood budget. However, the total cost of IVIg and SCIg, including administration costs, remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, time-driven, activity-based costing study to compare the costs of providing IVIg and SCIg to patients with HM from an Australian healthcare perspective. Ig product, consumables, equipment, and in-hospital costs were included. Analyses were conducted assuming full adherence and using (1) published prices for IVIg and SCIg, which excluded plasma fractionation costs to the Australian government, and (2) equivalent average weighted price for IVIg and SCIg, including plasma fractionation costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Annual IVIg product cost per patient was lower than that for SCIg under both costing scenarios: (1) AU$10,012 and (2) AU$5895, driven by higher SCIg doses. The costs of treating a patient with IVIg for a year were (1) AU$9936 and (2) AU$5787 lower than with SCIg, mainly due to higher SCIg product costs. When only in-hospital administration costs were considered (excluding Ig product and SCIg home consumables), SCIg treatment was AU$1019 less costly than IVIg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results indicated higher annual direct costs per patient treated with SCIg than IVIg, despite higher in-hospital costs associated with IVIg administration. Further research, including understanding costs to patients, is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10551-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:59:27Z","timestamp":1774684767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-5392","authenticated-orcid":false,"given":"Sara Carrillo","family":"de Albornoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Haysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Guglielmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Dunstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Rushford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karinna","family":"Saxby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelene","family":"Jesurajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomina","family":"Banahene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loo Sin","family":"Hoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa M.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"10551_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S (2019) The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol 10:33","journal-title":"Front Immunol"},{"issue":"6","key":"10551_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","volume":"20","author":"J Prevot","year":"2020","unstructured":"Prevot J, Jolles S (2020) Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol 20(6):557\u2013564","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10551_CR3","doi-asserted-by":"crossref","unstructured":"Carrillo de Albornoz S, Higgins AM, Petrie D, Irving A, Fanning L, Weinkove R et al (2024) Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. Blood Adv 8(9):2259-2267","DOI":"10.1182\/bloodadvances.2023012047"},{"key":"10551_CR4","unstructured":"National Blood Authority (2024) National Report on the Issue and Use of Immunoglobulin (Ig) Annual Report 2022\u20132023"},{"issue":"1","key":"10551_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","volume":"7","author":"KL Chai","year":"2023","unstructured":"Chai KL, Wong J, Weinkove R, Keegan A, Crispin P, Stanworth S et al (2023) Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Adv 7(1):20\u201331","journal-title":"Blood Adv"},{"key":"10551_CR6","doi-asserted-by":"crossref","unstructured":"Carrillo de Albornoz S, Chai KL, Higgins AM, Petrie D, Wood EM, McQuilten ZK (2024) A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies. Int J Technol Assess Health Care 40(1):e32","DOI":"10.1017\/S026646232400028X"},{"issue":"2","key":"10551_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM199107113250202","volume":"325","author":"JC Weeks","year":"1991","unstructured":"Weeks JC, Tierney MR, Weinstein MC (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325(2):81\u201386","journal-title":"N Engl J Med"},{"issue":"16","key":"10551_CR8","first-page":"1","volume":"17","author":"Health Quality Ontario","year":"2017","unstructured":"Health Quality Ontario (2017) Home-based subcutaneous infusion of immunoglobulin for primary and secondary immunodeficiencies: a health technology assessment. Ont Health Technol Assess Ser 17(16):1\u201386","journal-title":"Ont Health Technol Assess Ser"},{"issue":"5","key":"10551_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","volume":"36","author":"C Perraudin","year":"2016","unstructured":"Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O (2016) Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program. J Clin Immunol 36(5):502\u2013510","journal-title":"J Clin Immunol"},{"issue":"1","key":"10551_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","volume":"6","author":"B H\u00f6gy","year":"2005","unstructured":"H\u00f6gy B, Keinecke HO, Borte M (2005) Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 6(1):24\u201329","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10551_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13223-022-00735-6","volume":"18","author":"B Ritchie","year":"2022","unstructured":"Ritchie B, Martins KJB, Tran DT, Blain H, Richer L, Klarenbach SW (2022) Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study. Allergy Asthma Clin Immunol 18(1):99","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10551_CR12","unstructured":"National Blood Authority. Evaluate and develop options to improve access to subcutaneous immunoglobulin (SCIg), Final Report"},{"key":"10551_CR13","doi-asserted-by":"crossref","unstructured":"Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA (2019) Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang 114(3):237-46","DOI":"10.1111\/vox.12760"},{"key":"10551_CR14","doi-asserted-by":"crossref","unstructured":"Kaplan RS, Witkowski M, Abbott M, Guzman AB, Higgins LD, Meara JG, et al (2014) Using time-driven activity-based costing to identify value improvement opportunities in healthcare. J Healthc Manag 59(6):399-412","DOI":"10.1097\/00115514-201411000-00005"},{"key":"10551_CR15","doi-asserted-by":"crossref","unstructured":"Keel G, Savage C, Rafiq M, Mazzocato P (2017) Time-driven activity-based costing in health care: a systematic review of the literature. Health Policy 121(7):755-63","DOI":"10.1016\/j.healthpol.2017.04.013"},{"key":"10551_CR16","doi-asserted-by":"crossref","unstructured":"Etges APBdS, Ruschel KB, Polanczyk CA, Urman RD (2020) Advances in value-based healthcare by the application of time-driven activity-based costing for inpatient management: a systematic review. Value in Health 23(6):812-23","DOI":"10.1016\/j.jval.2020.02.004"},{"key":"10551_CR17","doi-asserted-by":"crossref","unstructured":"Etges APBdS, Polanczyk CA, Urman RD (2020) A standardized framework to evaluate the quality of studies using TDABC in healthcare: the TDABC in Healthcare Consortium Consensus Statement. BMC Health Services Research. 20(1):1107","DOI":"10.1186\/s12913-020-05869-0"},{"key":"10551_CR18","doi-asserted-by":"crossref","unstructured":"Burns KE, Haysom HE, Higgins AM, Waters N, Tahiri R, Rushford\u00a0K et al (2019) A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. Transfus Med 29(1):33\u201340","DOI":"10.1111\/tme.12523"},{"key":"10551_CR19","doi-asserted-by":"crossref","unstructured":"McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, et al (2019) The cost of blood: a study of the total cost of red blood cell transfusion in patients with \u03b2-thalassemia using time-driven activity-based costing. Transfusion. 59(11):3386-95","DOI":"10.1111\/trf.15558"},{"key":"10551_CR20","unstructured":"BloodStar (2024) Criteria for clinical use of immunoglobulin in Australia:\u00a0acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT). Available from:\u00a0https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621"},{"key":"10551_CR21","unstructured":"Victoria Department of Health (2024) Subcutaneous immunoglobulin\u00a0(SCIg) access program. [Available from: https:\/\/www.health.vic.gov.au\/patient-care\/subcutaneous-immunoglobulinscig-access-program"},{"key":"10551_CR22","doi-asserted-by":"crossref","unstructured":"Crispin P, Henderson R, Yun J, Crosbie C, Tognarini D, Youssef\u00a0S, et al (2024) Outcomes of a patient support programme for subcutaneous immunoglobulin therapy in patients with primary or secondary immunodeficiencies or chronic inflammatory demyelinating polyneuropathy. Intern Med J 54(11):1827-37","DOI":"10.1111\/imj.16520"},{"key":"10551_CR23","unstructured":"National Blood Authority (2025) BloodNet for blood products from\u00a0Lifeblood. [Available from: https:\/\/www.blood.gov.au\/bloodproducts\/access-and-ordering\/bloodnet-blood-productslifeblood"},{"key":"10551_CR24","unstructured":"Independent Health and Aged Care Pricing Authority (2023) National Hospital Cost Data Collection (NHCDC) Public Sector 2022\u201323"},{"key":"10551_CR25","unstructured":"EPPI Centre (2024) CCEMG\u2013EPPI Centre Cost Converter v.1.7. [Available from:\u00a0https:\/\/eppi.ioe.ac.uk\/costconversion\/"},{"key":"10551_CR26","unstructured":"Independent Health and Aged Care Pricing Authority (2024) Tier 2 Non-Admitted Services Compendium https:\/\/eppi.ioe.ac.uk\/costconversion\/"},{"key":"10551_CR27","doi-asserted-by":"crossref","unstructured":"Alsina L, Montoro JB, Moral PM, Neth O, Pica MO, S\u00e1nchez-Ram\u00f3n S, et al (2022) Cost minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. Eur J Health Econ 23(3):551-8","DOI":"10.1007\/s10198-021-01378-x"},{"key":"10551_CR28","doi-asserted-by":"crossref","unstructured":"Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, et al (2022) A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Curr Oncol 30(1):274-83","DOI":"10.3390\/curroncol30010022"},{"key":"10551_CR29","doi-asserted-by":"crossref","unstructured":"Windegger TM, English J, Weston H, Morwood K, Kynn M, Scuffham P, et al (2021) Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy. Asia Pac J Clin Oncol 17(6):546-54","DOI":"10.1111\/ajco.13515"},{"key":"10551_CR30","doi-asserted-by":"crossref","unstructured":"Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, et al (2021) Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol 106(4):439-49","DOI":"10.1111\/ejh.13580"},{"issue":"4","key":"10551_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.hemonc.2021.01.001","volume":"14","author":"I Pasic","year":"2021","unstructured":"Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, Kim DDH et al (2021) Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use. Hematol Oncol Stem Cell Ther 14(4):302\u2013310","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10551-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:41:24Z","timestamp":1776235284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10551-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10551"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10551-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Monash University and Monash Health Human Research Ethics Committee (RES-22-0000-477Q \u2013 88781). As per the ethics committee review, individual patient consent was not required as no identifiable patient information was collected. The study was conducted in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Erica Wood and Zoe McQuilten received research funding to institution from Abbvie, Amgen, AstraZeneca, Beigene, Celgene, Janssen, Novartis, Sanofi and Takeda. Terri Dunstan participated in the Subcutaneous Immunoglobulin Nurse Advisory Board organised by Commonwealth Serum Laboratory Behring LTD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}